ExonHit Reports Proof-of-Concept In Breast Cancer Diagnostic Using Its SpliceArray(TM) Platform

News — By on March 17, 2009 at 12:00 am

ExonHit Therapeutics (Alternext: ALEHT) reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1]. Study data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular characteristics of breast malignancy.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback